CA2864264C - Pharmaceutical compositions for combination therapy - Google Patents

Pharmaceutical compositions for combination therapy Download PDF

Info

Publication number
CA2864264C
CA2864264C CA2864264A CA2864264A CA2864264C CA 2864264 C CA2864264 C CA 2864264C CA 2864264 A CA2864264 A CA 2864264A CA 2864264 A CA2864264 A CA 2864264A CA 2864264 C CA2864264 C CA 2864264C
Authority
CA
Canada
Prior art keywords
tesofensine
pharmaceutically acceptable
acceptable salt
use according
metoprolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2864264A
Other languages
English (en)
French (fr)
Other versions
CA2864264A1 (en
Inventor
Henrik Bjork Hansen
Morten Grunnet
Bo Hjorth BENTZEN
Lars HYVELED-NIELSEN
Jorgen Buus Lassen
Claus Sundgreen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Saniona AS
Original Assignee
Saniona AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona AS filed Critical Saniona AS
Publication of CA2864264A1 publication Critical patent/CA2864264A1/en
Application granted granted Critical
Publication of CA2864264C publication Critical patent/CA2864264C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864264A 2012-02-16 2013-02-14 Pharmaceutical compositions for combination therapy Active CA2864264C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261599623P 2012-02-16 2012-02-16
US61/599,623 2012-02-16
DKPA201270076 2012-02-16
DKPA201270076 2012-02-16
PCT/EP2013/052941 WO2013120935A1 (en) 2012-02-16 2013-02-14 Pharmaceutical compositions for combination therapy

Publications (2)

Publication Number Publication Date
CA2864264A1 CA2864264A1 (en) 2013-08-22
CA2864264C true CA2864264C (en) 2020-05-05

Family

ID=48983571

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864264A Active CA2864264C (en) 2012-02-16 2013-02-14 Pharmaceutical compositions for combination therapy

Country Status (14)

Country Link
US (5) US9211271B2 (enExample)
EP (1) EP2814473B1 (enExample)
JP (1) JP6203760B2 (enExample)
CN (3) CN108434129A (enExample)
AU (1) AU2013220424B2 (enExample)
CA (1) CA2864264C (enExample)
DK (1) DK2814473T3 (enExample)
EA (1) EA029543B1 (enExample)
ES (1) ES2704987T3 (enExample)
HR (1) HRP20190050T1 (enExample)
LT (1) LT2814473T (enExample)
PL (1) PL2814473T3 (enExample)
SI (1) SI2814473T1 (enExample)
WO (1) WO2013120935A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029543B1 (ru) * 2012-02-16 2018-04-30 Саниона А/С Способ лечения, профилактики или уменьшения сердечно-сосудистых побочных эффектов тезофенсина
EP3087798A4 (en) * 2013-12-28 2017-08-30 Intel Corporation System and method for device action and configuration based on user context detection from sensors in peripheral devices
HUE055974T2 (hu) 2015-03-03 2022-01-28 Saniona As Tesofensine és metoprolol kombinációs készítmény
US20190060301A1 (en) 2016-01-15 2019-02-28 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
KR20190050784A (ko) 2016-09-07 2019-05-13 사니오나 에이/에스 테소펜신 조성물
WO2020144146A1 (en) 2019-01-07 2020-07-16 Saniona A/S Tesofensine for reduction of body weight in prader-willi patients
CN110297826B (zh) * 2019-05-31 2020-12-11 南京理工大学 基于json动态解析卫星遥测数据的方法
MX2022013236A (es) 2020-04-22 2023-01-24 Saniona As Tratamiento de la obesidad hipotalamica.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2106494A1 (en) 1991-03-18 1992-09-19 James W. Young Composition and method containing optically pure (s) metoprolol
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
CA2553649A1 (en) 2004-01-22 2005-08-04 Neurosearch A/S Compounds for the sustained reduction of body weight
WO2009065845A1 (en) 2007-11-20 2009-05-28 Neurosearch A/S A method for treating over-eating disorders
US20100317572A1 (en) 2007-12-20 2010-12-16 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
US9408837B2 (en) 2008-05-28 2016-08-09 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
EA029543B1 (ru) * 2012-02-16 2018-04-30 Саниона А/С Способ лечения, профилактики или уменьшения сердечно-сосудистых побочных эффектов тезофенсина
HUE055974T2 (hu) * 2015-03-03 2022-01-28 Saniona As Tesofensine és metoprolol kombinációs készítmény

Also Published As

Publication number Publication date
JP6203760B2 (ja) 2017-09-27
US20160074344A1 (en) 2016-03-17
US9387184B2 (en) 2016-07-12
JP2015508765A (ja) 2015-03-23
EP2814473A1 (en) 2014-12-24
CN108434129A (zh) 2018-08-24
WO2013120935A1 (en) 2013-08-22
PL2814473T3 (pl) 2019-06-28
US20220016055A1 (en) 2022-01-20
EA201491532A1 (ru) 2015-01-30
LT2814473T (lt) 2019-01-25
US20170007557A1 (en) 2017-01-12
US20180185304A1 (en) 2018-07-05
US9211271B2 (en) 2015-12-15
CN108853071A (zh) 2018-11-23
ES2704987T3 (es) 2019-03-21
SI2814473T1 (sl) 2019-03-29
EA029543B1 (ru) 2018-04-30
EP2814473B1 (en) 2018-10-10
CN104244935A (zh) 2014-12-24
US20150025107A1 (en) 2015-01-22
DK2814473T3 (en) 2019-01-28
AU2013220424B2 (en) 2017-03-23
CA2864264A1 (en) 2013-08-22
HK1204946A1 (en) 2015-12-11
AU2013220424A1 (en) 2014-09-25
HRP20190050T1 (hr) 2019-03-08

Similar Documents

Publication Publication Date Title
US20220016055A1 (en) Pharmaceutical Compositions For Combination Therapy
US9901568B2 (en) Pharmaceutical compositions of 5-hydroxytryptophan and serotonin-enhancing compound
JP5698282B2 (ja) 痛みの治療のための混合されたＯＲＬ１／μ−アゴニスト
US20160256449A1 (en) H3 receptor antagonist for use in the treatment of alzheimer's disease
WO2010026154A1 (en) A method for combating adverse effects arising from antipsychotic treatment
AU2005205880B2 (en) Compounds for the sustained reduction of body weight
MX2011001631A (es) Tratamiento de transtornos de ansiedad.
HK1204946B (en) Pharmaceutical compositions for combination therapy
CN102858339B (zh) 用于治疗疼痛的血清素和去甲肾上腺素再摄取抑制剂与类鸦片激动剂的组合
WO2009080693A2 (en) Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
KR20220108123A (ko) 치매 환자의 행동 및 심리적 증상 치료

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180212

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250814

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106